Showing results (1-10 of 127) with videos related to
Sort By:
Pageof 13
Cancer Research|August 3, 2021
Improving Tumor Penetration of Antibodies and Antibody-Drug Conjugates: Taking Away the Barriers for Trojan HorsesGuus A M S van DongenJournal of Cardiovascular Translational Research|May 6, 2011
EATRIS, a vision for translational research in EuropeRegina Becker, Guus A M S van DongenDrug Discovery Today. Technologies|July 4, 2014
(89)Zr-labeled compounds for PET imaging guided personalized therapyDanielle J Vugts, Guus A M S van DongenBioconjugate Chemistry|May 11, 2021
State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PETMarion Chomet, Guus A M S van Dongen, Danielle J VugtsCancer Biotherapy & Radiopharmaceuticals|August 17, 2010
Immuno-positron emission tomography: shedding light on clinical antibody therapyGuus A M S van Dongen, Maria J W D VosjanOral Oncology|November 27, 2010
The potential role of non-FDG-PET in the management of head and neck cancerDerrek A Heuveling, Remco de Bree, Guus A M S van DongenTumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 25, 2012
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PETGuus A M S van Dongen, Alex J Poot, Danielle J VugtsEJNMMI Radiopharmacy and Chemistry|May 11, 2024
Good practices for <sup>89</sup>Zr radiopharmaceutical production and quality controlThomas Erik Wuensche, Serge Lyashchenko, Guus A M S van Dongen, et al.Current Topics in Medicinal Chemistry|February 26, 2013
89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicalsDanielle J Vugts, Gerard W M Visser, Guus A M S van DongenDrug Discovery Today|July 7, 2012
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PETPaul Slobbe, Alex J Poot, Albert D Windhorst, et al.Pageof 13